Moleculin Biotech, Inc. (NASDAQ:MBRX) Sees Significant Growth in Short Interest

Moleculin Biotech, Inc. (NASDAQ:MBRX) saw a large growth in short interest in the month of May. As of May 29th, there was short interest totaling 828,958 shares, a growth of 57.1% from the May 14th total of 527,786 shares. Based on an average daily trading volume, of 263,322 shares, the short-interest ratio is presently 3.1 days. Approximately 15.7% of the company’s stock are sold short.

Moleculin Biotech Stock Performance

NASDAQ MBRX opened at $2.80 on Thursday. The firm has a market cap of $14.95 million, a PE ratio of -0.16 and a beta of 1.77. Moleculin Biotech has a one year low of $1.79 and a one year high of $24.00. The firm’s fifty day moving average is $2.49 and its two-hundred day moving average is $3.31.

Moleculin Biotech (NASDAQ:MBRX) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($3.54) EPS for the quarter, missing analysts’ consensus estimates of ($2.33) by ($1.21). Research analysts predict that Moleculin Biotech will post -5.1 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Moleculin Biotech stock. Jane Street Group LLC acquired a new stake in Moleculin Biotech, Inc. (NASDAQ:MBRX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned 1.11% of Moleculin Biotech as of its most recent filing with the Securities and Exchange Commission (SEC). 15.52% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on MBRX shares. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price objective on shares of Moleculin Biotech in a research report on Tuesday, March 24th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Moleculin Biotech in a research report on Tuesday, April 21st. Finally, Wall Street Zen cut shares of Moleculin Biotech from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $22.00.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.